Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Company

WuXi AppTec Expands Peptide Manufacturing Capacity with Two New Plants in China

Fineline Cube Jan 10, 2024

WuXi AppTec (HKG: 2359, SHA: 603259), a leading China-based Contract Research, Development, and Manufacturing Organization...

Company Medical Device

Sino Medical Sciences’ HT Supreme Drug-Eluting Stent System Gains Market Approval in Bangladesh

Fineline Cube Jan 10, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a Chinese medical device company, has announced that...

Company Drug

Novartis’s Cosentyx Secures Additional Indication for Psoriatic Arthritis in China

Fineline Cube Jan 10, 2024

Swiss pharmaceutical giant Novartis (SWX: NOVN) has announced that its drug Cosentyx (secukinumab), which targets...

Company Drug

Pfizer and Genmab’s Tivdak Earns Priority Review from FDA for Full Registration

Fineline Cube Jan 10, 2024

The US Food and Drug Administration (FDA) has accepted for priority review a filing from...

Company

International Society for Cell & Gene Therapy Comments on FDA’s CAR-T Investigation

Fineline Cube Jan 10, 2024

The International Society for Cell & Gene Therapy (ISCT) has published a statement addressing the...

Company Hospital

Meizhong Jiahe Medical Debuts on Hong Kong Stock Exchange Below IPO Price

Fineline Cube Jan 10, 2024

China-based Meizhong Jiahe Medical Science & Technology Development Co., Ltd has completed its initial public...

Company Drug Medical Device

AbbVie Launches Continuous Infusion Therapy for Advanced Parkinson’s Disease in EU

Fineline Cube Jan 10, 2024

AbbVie (NYSE: ABBV) has announced the launch of its dopamine replacement therapy, Produodopa (foslevodopa +...

Company Drug

OBI Pharma Gets US FDA Green Light for TROP2 Targeting ADC Cancer Therapy Clinical Study

Fineline Cube Jan 10, 2024

OBI Pharma (4174.TWO), partner to Biosion Inc., has announced that it has received approval from...

Company Deals

Bio-Link Partners with Verdot to Distribute Innovative Bioprocessing Products in China

Fineline Cube Jan 10, 2024

Bio-Link Biological Applied Technologies (Shanghai) Co., Ltd., a leading provider of life sciences industry solutions...

Company Deals

Synvida Raises Nearly RMB 200 Million in Series A Funding to Advance Clinical Studies

Fineline Cube Jan 10, 2024

Synvida, a biotech company incubated by Shanghai Pharma (HKG: 2607, SHA: 601607) and Shanghai Healthcare...

Company Deals Medical Device

Sinocare Partners with Illumina to Localize iScan Chip Scanners for Precision Health Applications

Fineline Cube Jan 10, 2024

Sinocare Inc. (SHE: 300298), a China-based company, has entered into a partnership agreement with U.S....

Company Deals

Johnson & Johnson to Acquire Ambrx Biopharma in a Deal Valued at USD 2 Billion

Fineline Cube Jan 9, 2024

Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare conglomerate, has announced its intention to...

Company Drug

MSD’s Gardasil 9 Receives NMPA Approval for Two-Dose Schedule in Younger Females

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a prominent pharmaceutical company in the U.S., has...

Company Drug

Astellas’ Zolbetuximab Faces FDA Rejection Due to Manufacturing Facility Deficiencies

Fineline Cube Jan 9, 2024

The US Food and Drug Administration (FDA) has issued a rejection for a filing submitted...

Company Drug

3SBio Inc. Receives NMPA Approval for OTC Minoxidil Foam for Male Hair Loss Treatment

Fineline Cube Jan 9, 2024

3SBio Inc., a leading biopharmaceutical company based in China (HKG: 1530), has announced that it...

Company Deals

MSD to Acquire Harpoon Therapeutics for USD 680 Million, Expanding Its Oncology Pipeline

Fineline Cube Jan 9, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has announced its...

Company

Eli Lilly Appoints First Female Leader for China Unit with Huzur Devletsah at the Helm

Fineline Cube Jan 9, 2024

Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the U.S., has announced...

Company Drug

Jiangxi Jemincare Group Receives Clinical Trial Approvals for Two Innovative Biologics in the US and China

Fineline Cube Jan 9, 2024

Jiangxi Jemincare Group, a biopharmaceutical company based in China, has announced that it has received...

Company Medical Device

ShuWen Biotech’s MammaTyper Diagnostic Kit Receives NMPA Approval for Breast Cancer Molecular Classification

Fineline Cube Jan 9, 2024

ShuWen Biotech Co., Ltd, a biopharmaceutical company based in Zhejiang, has announced that its MammaTyper...

Company Drug

Allist Pharmaceuticals’ Furmonertinib and AstraZeneca’s Enhertu Earn Breakthrough Designations in China for NSCLC Treatments

Fineline Cube Jan 9, 2024

The Center for Drug Evaluation (CDE) in China has indicated on its website that Allist...

Posts pagination

1 … 456 457 458 … 704

Recent updates

  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
  • RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal
  • Eli Lilly Reports Record Q2 2026 Revenue of $22.97B, Driven by Tirzepatide Blockbusters and Raises Full-Year Guidance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Others

Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects

Company

RemeGen Forecasts H1 2026 Revenue of RMB 5.85B, Net Profit of RMB 4.70B on Telitacicept and AbbVie Licensing Deal

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.